Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225895 | 0.71 | KMT2A (0.48) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4413253 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL2910271 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4412005 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4631171 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4408869 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4405820 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL9661487 | 0.68 | ALDH1A1 (0.40) | ALDH1A1NPSR1 | |
| SCHEMBL15183811 | 0.67 | ALDH1A1 (0.46) | ALDH1A1CYP1A2LMNANPSR1 | |
| SCHEMBL21721550 | 0.67 | ALDH1A1 (0.37) | ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174246-B2 | Direct AMPK activators | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | MIDCAP FINANCIAL TRUST | 2018-02-22 | — | — | US | disclosed |
| WO-2012085167-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174246-B2 | Direct AMPK activators | PRKAA1, PRKAG1, PRKAB1 | ALDH1A1 490/4885CYP1A2 1665/4885LMNA 2265/4885 |
| US-20180051006-A1 | DIRECT AMPK ACTIVATORS | PRKAA1, PRKAG1, PRKAB1 | ALDH1A1 490/4885CYP1A2 1665/4885LMNA 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.